Aiobio아이오바이오
447690 · KONEX · ₩447690 · 아이오바이오
- Market cap
- ₩5.5B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−55.7% from the high
₩1,702Today: ₩1,720 – ₩2,290₩4,510
Returns
- 1W−0.1%
- 1M−11.9%
- 3M−25.1%
- 6M−35.5%
- YTD−35.5%
- 1Y−40.5%
- Volume today
- 10
- 0.1× the 20-day average
- Traded today
- ₩19,437
- Listed shares
- 2,772,756
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 27 of 100 (50 is a normal day for this stock).
- MomentumFlat-1.5% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Aiobio stock overview
Aiobio (아이오바이오, KRX: 447690) is listed on KONEX, in the Medical & precision devices sector. , founded in August 2011, develops and sells dental diagnostic medical devices that use biofluorescence image screening to detect oral conditions such as plaque, tartar, caries and enamel cracks. Its shares closed at ₩1,999 on Oct 29, 2026, unchanged on the day, giving it a market value of ₩5.5B.
Key facts
- Market cap
- ₩5.5B
- Sector
- Medical & precision devices
- Latest price change
- 0.00%
- As of
- Oct 29, 2026
- Main business
- , founded in August 2011, develops and sells dental diagnostic medical devices that use biofluorescence image screening to detect oral conditions such as plaque, tartar, caries and enamel cracks.
Quick answers about Aiobio
- What does Aiobio do?
- , founded in August 2011, develops and sells dental diagnostic medical devices that use biofluorescence image screening to detect oral conditions such as plaque, tartar, caries and enamel cracks. Its products include the Qraycam Pro and Qraypen C intraoral devices, the Qray software, and the Cariview device, along with oral care products such as fluoride toothpaste. The company also offers LINKDENS, an oral health management software service in trial rollout since the second half of 2024, and sells its devices in South Korea and is pursuing overseas markets.
- What is the market cap of Aiobio?
- The market capitalisation of Aiobio was ₩5.5B at the close on Oct 29, 2026.
- Who are the largest shareholders of Aiobio?
- According to the latest official filings, the largest reported holders are A&I (26.72%, as of Oct 15, 2025); DSC Investment (13.13%, as of Jul 8, 2026); Evergreen Investment Partners (0.28%, as of Mar 11, 2025).
- When is the next earnings report from Aiobio?
- Korean companies rarely announce results dates in advance. Based on when Aiobio filed the same report in past years, its next annual results is expected around Mar 21, 2027.
Company profile
IOBIO Co., Ltd., founded in August 2011, develops and sells dental diagnostic medical devices that use biofluorescence image screening to detect oral conditions such as plaque, tartar, caries and enamel cracks. Its products include the Qraycam Pro and Qraypen C intraoral devices, the Qray software, and the Cariview device, along with oral care products such as fluoride toothpaste. The company also offers LINKDENS, an oral health management software service in trial rollout since the second half of 2024, and sells its devices in South Korea and is pursuing overseas markets.
Written by AI from the company's latest annual report.
- Korean name
- 아이오바이오
- CEO
- 윤홍철
- Founded
- Aug 2011
- Listed
- Dec 2022
- Listed shares
- 2,772,756
- Fiscal year ends
- Month 12
- Website
- www.aiobio.co.kr/
Similar companies
- TSE131290 · ₩2.9T₩260,500−5.27%
- Kctech281820 · ₩1.9T₩97,500+2.09%
- Classys214150 · ₩1.7T₩26,800−0.74%
- Park Systems140860 · ₩1.6T₩228,500−0.44%
- DI003160 · ₩1.2T₩43,500+0.46%
- Curiox Biosystems445680 · ₩1T₩60,600−2.88%
- LivsMed491000 · ₩1T₩40,450−7.33%
- Seers458870 · ₩907B₩23,650−3.86%
Recent filings
See all- Investor relations (IR) eventOct 7, 2026
- Investor relations (IR) eventSep 17, 2026
- Insider shareholding reportJul 8, 2026
- 5%+ holding reportJul 8, 2026
- Insider shareholding reportJun 9, 2026
Titles in Korean until English translations are added.
Also known as: Aiobio / 아이오바이오 / 447690 / KRX:447690
Source: KRX statistical information